The AMNOG process in Germany
Procedural steps, institutions, timeline and the reimbursement pathway.
AMNOG / Germany
AMNOG in Germany: benefit-assessment guidance and insights
AMNOG is Germany's framework for early benefit assessment and reimbursement pricing of new medicines. These guides explain the process, legal framework, German dossier and interface with the EU Joint Clinical Assessment.
AMNOG guides
AMNOG legislation in Germany
SGB V, AM-NutzenV and the legal framework for benefit assessment and pricing.
The AMNOG dossier
Modules, German evidence requirements and dossier traceability.
JCA dossier and AMNOG dossier
European clinical evidence and the national German additions that remain necessary.
Connect European evidence with German added benefit
The national interpretation of European evidence starts before dossier submission: with comparator choice, patient populations, endpoints and a robust Delta-Dossier strategy.